Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications

"Vorasidenib and Low-Grade Glioma: INDIGO Incremental Insights".

"Vorasidenib and Low-Grade Glioma: INDIGO Incremental Insights".

Journal: Neuro-oncology
Published: December 08, 2025

Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas.

Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas.

Journal: Annual review of pathology
Published: November 18, 2025

Comparing Isocitrate Dehydrogenase Inhibitors with Procarbazine, Lomustine, and Vincristine Chemotherapy for Oligodendrogliomas.

Comparing Isocitrate Dehydrogenase Inhibitors with Procarbazine, Lomustine, and Vincristine Chemotherapy for Oligodendrogliomas.

Journal: Cancers
Published: November 13, 2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma.

Journal: International journal of clinical oncology
Published: October 25, 2025

Vorasidenib as monotherapy in grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Vorasidenib as monotherapy in grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Journal: Bulletin du cancer
Published: October 07, 2025

Open questions on vorasidenib.

Open questions on vorasidenib.

Journal: Current opinion in oncology
Published: October 01, 2025

Understanding and imaging PHGDH-driven intrinsic resistance to mutant IDH inhibition in gliomas.

Understanding and imaging PHGDH-driven intrinsic resistance to mutant IDH inhibition in gliomas.

Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025

IDH Mutations and Intraoperative 5-ALA Fluorescence in Gliomas: A Systematic Literature Review with Novel Exploratory Hypotheses on the Modulatory Effect of Vorasidenib.

IDH Mutations and Intraoperative 5-ALA Fluorescence in Gliomas: A Systematic Literature Review with Novel Exploratory Hypotheses on the Modulatory Effect of Vorasidenib.

Journal: Cancers
Published: August 19, 2025

The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment.

The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment.

Journal: Current opinion in neurology
Published: August 13, 2025

New biochemical approaches for the treatment of glioblastoma.

New biochemical approaches for the treatment of glioblastoma.

Journal: The Journal of biological chemistry
Published: August 02, 2025

Drug-induced liver injury: a real-world pharmacovigilance study using the FDA adverse event reporting system database 2004-2024.

Drug-induced liver injury: a real-world pharmacovigilance study using the FDA adverse event reporting system database 2004-2024.

Journal: Annals of hepatology
Published: July 18, 2025

Molecularly driven therapies in the treatment of primary brain tumors.

Molecularly driven therapies in the treatment of primary brain tumors.

Journal: Advances in cancer research
Published: July 17, 2025
Showing 1-12 of 86

Last Updated: 01/07/2026